论文部分内容阅读
目的探讨布地奈德雾化吸入对轻、中度支气管哮喘患者Th1/Th2细胞因子平衡的影响。方法将70例轻、中度支气管哮喘患者随机平分为两组,均按上述治疗方法治疗,并分别采用ELISA法检测两组哮喘患者治疗前及治疗后1、2个月的外周血清白细胞介素-5(IL-5)、白细胞介素-12(IL-12)和干扰素-γ(IFN-γ)的水平,对其检测结果进行分析总结。结果治疗组经布地奈德雾化吸入治疗1、2个月后,患者外周血清IL-5水平较治疗前明显降低,IL-12和IFN-γ水平较治疗前上升(P<0.05)。治疗组患者治疗后1、2月外周血清IL-5、IL-12和IFN-γ的水平均较对照组明显好转。结论布地奈德雾化吸入对轻、中度支气管哮喘患者可有效降低IL-5水平,升高IL-12水平与IFN-γ,并抑制炎症介质释放,调节Th1/Th2细胞因子间失平衡。
Objective To investigate the effect of inhaled budesonide on the balance of Th1 / Th2 cytokines in patients with mild or moderate bronchial asthma. Methods Seventy patients with mild or moderate bronchial asthma were randomly divided into two groups according to the above treatment methods. The serum levels of interleukin (IL-5), interleukin-12 (IL-12) and interferon-γ (IFN-γ) were measured and the results of their detection were analyzed and summarized. Results After treated with budesonide inhalation for 1 and 2 months, the level of IL-5 in peripheral blood of patients in treatment group was significantly lower than that before treatment, and the levels of IL-12 and IFN-γ increased (P <0.05). The serum levels of IL-5, IL-12 and IFN-γ in the treatment group were significantly improved compared with those in the control group at 1 month and 2 months after treatment. Conclusion Inhaled inhalation of budesonide can effectively reduce the level of IL-5, increase the level of IL-12 and IFN-γ, inhibit the release of inflammatory mediators and regulate the imbalance of Th1 / Th2 cytokines in mild and moderate bronchial asthma patients.